| Trial ID: | L2257 |
| Source ID: | NCT00461630
|
| Associated Drug: |
Er Niacin/Laropiprant
|
| Title: |
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
|
| Acronym: |
HPS2-THRIVE
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00461630/results
|
| Conditions: |
Cardiovascular Disease|Peripheral Arterial Disease|Diabetes Mellitus|Coronary Heart Disease
|
| Interventions: |
DRUG: ER niacin/laropiprant|DRUG: simvastatin|DRUG: ezetimibe/simvastatin
|
| Outcome Measures: |
Primary: Major Vascular Event, Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation, During scheduled treatment period (median duration 3.9 years) | Secondary: Major Coronary Events, Non-fatal myocardial infarction (MI) or coronary death, During scheduled treatment period (median duration 3.9 years)|Stroke, Fatal or non-fatal, During scheduled treatment period (median duration 3.9 years)|Coronary or Non-coronary Revascularisation, During scheduled treatment period (median duration 3.9 years)|Mortality, All-cause mortality, During scheduled treatment period (median duration 3.9 years)
|
| Sponsor/Collaborators: |
Sponsor: University of Oxford | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
25673
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2007-01
|
| Completion Date: |
2012-10
|
| Results First Posted: |
2014-01-28
|
| Last Update Posted: |
2014-02-28
|
| Locations: |
Clinical Trial Service Unit, University of Oxford, Oxford, OX3 7LF, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00461630
|
